Keywords: NTRK gene fusion, papillary thyroid cancer, clinicogenomic, epidemiology, biobank. Click here to sign up for free Altmetric alerts about this article.

The FDA has granted full approval to Bayer’s Vitrakvi (larotrectinib), a first-in-class NTRK inhibitor, for the treatment of adult and pediatric patients with NTRK gene fusion-positive solid tumors.

With its June approval of Augtyro (repotrectinib) for patients with solid tumors harboring an NTRK gene fusion, the agency has made another treatment option available for adult and some pediatric ...

NTRK gene fusion is a rare genetic alteration found in tumors originating from various organs, including the lungs, thyroid, and intestines. VITRAKVI is indicated for patients with advanced or ...

The drug is now fully approved in the United States for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired ...

Report Ocean recently released a new report on the global NTRK Fusion Gene Positive Advanced Solid Tumor Market. This study report is a combination of data and analysis gleaned from several sources to ...

The FDA granted accelerated approval to repotrectinib for the treatment of adults and children 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion.

WHIPPANY, N.J., April 10, 2025--U.S. FDA Grants Full Approval of VITRAKVI® (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors ...

NTRK Fusion Gene Positive Advanced Solid Tumor Market Growth 2023-2031, Covid 19 Outbreak Impact research report added by Report Ocean, is an in-depth analysis of market characteristics, size and ...